bioMérieux Logo

bioMérieux

Provides in vitro diagnostic solutions for clinical and industrial microbiology.

BIM | PA

Overview

Corporate Details

ISIN(s):
FR0013280286 (+13 more)
LEI:
549300AK8Y0LBIQ4T071
Country:
France
Address:
376 CHE DE L'ORME, 69280 MARCY-L'ETOILE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

bioMérieux is a global leader in the field of in vitro diagnostics, dedicated to improving public health worldwide. Since its founding in 1963, the company has developed and provided comprehensive diagnostic solutions—including systems, reagents, software, and services—that enable critical decision-making for clinicians and industrial quality control professionals. The company's activities are focused on two primary areas: clinical diagnostics and industrial microbiology. In the clinical market, its solutions support the diagnosis of infectious diseases, management of sepsis, cardiovascular emergencies, and antimicrobial stewardship. For industrial applications, bioMérieux offers microbiological testing solutions to ensure the safety and quality of food, pharmaceutical, and cosmetic products. The portfolio features advanced systems like BIOFIRE® (multiplex PCR), VITEK® (microbial identification), and BACT/ALERT® (automated blood culture) to deliver rapid and reliable results.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-02 11:11
Declaration of Voting Results & Voting Rights Announcements
Août 2025 - Déclaration sur le nombre d'actions composant le capital social et …
French 106.1 KB
2025-08-05 09:41
Declaration of Voting Results & Voting Rights Announcements
Juillet 2025 - Déclaration sur le nombre d'actions composant le capital social …
French 105.8 KB
2025-06-16 07:01
M&A Activity
bioMérieux strengthens its next-generation sequencing capabilities with the acq…
English 222.9 KB
2025-06-16 07:01
M&A Activity
bioMérieux renforce ses capacités de séquençage de nouvelle génération avec l’a…
French 248.3 KB
2025-06-03 16:05
Declaration of Voting Results & Voting Rights Announcements
Mai 2025 - Déclaration sur le nombre d'actions composant le capital social et s…
French 106.1 KB
2025-06-03 07:01
Environmental & Social Information
bioMérieux launches cutting-edge equine infectious respiratory disease testing
English 276.4 KB
2025-06-03 07:01
Regulatory News Service
bioMérieux lance un test diagnostic innovant pour détecter les maladies respira…
French 274.0 KB
2025-05-05 11:37
Declaration of Voting Results & Voting Rights Announcements
Avril 2025 - Déclaration sur le nombre d'actions composant le capital social et…
French 106.1 KB
2025-04-22 07:01
Environmental & Social Information
WATCHFIRE™ by bioMérieux: a PCR test to detect viruses and bacteria in wastewat…
English 277.8 KB
2025-04-22 07:01
Regulatory News Service
WATCHFIRE™, un nouveau test PCR développé par bioMérieux pour détecter les viru…
French 267.8 KB
2025-04-17 07:01
Investor Presentation
bioMérieux – First-Quarter 2025 Business Review
English 325.6 KB
2025-04-17 07:01
Earnings Release
bioMérieux – Information financière du 1er trimestre 2025
French 281.7 KB
2025-04-07 07:01
Regulatory News Service
bioMérieux obtains CE-marking for LUMED™ APSS™, a cutting-edge software solutio…
English 276.6 KB
2025-04-07 07:01
Business and Financial Review
bioMérieux obtient le marquage CE pour LUMED™ APSS™, une solution logicielle de…
French 262.7 KB
2025-04-02 14:13
Declaration of Voting Results & Voting Rights Announcements
Mars 2025 - Déclaration sur le nombre d'actions composant le capital social et …
French 106.1 KB

Automate Your Workflow. Get a real-time feed of all bioMérieux filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for bioMérieux via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-09-04 N/A Other Sell 1,432 137,517.82 EUR
2023-09-04 N/A Other Sell 1,253 120,328.10 EUR
2023-09-01 N/A Other Other 2,900 N/A
2023-06-23 N/A Other Other 323 24,971.13 EUR
2023-06-23 N/A Other Buy 323 24,971.13 EUR
2023-06-23 N/A Other Buy 300 23,193.00 EUR
2023-06-23 N/A Other Buy 25 1,932.75 EUR
2023-03-23 N/A Other Sell 16,500 1,650,415.80 EUR

Peer Companies

Company Country Ticker View
Oncodesign Precision Medicine S.A Logo
Develops precision therapies & diagnostics for resistant and metastatic cancers.
France ALOPM
Oncoinvent ASA Logo
Developing alpha-emitting radiotherapies for treating cancers in the peritoneal cavity.
Norway OCIN
Oncolys BioPharma Inc. Logo
Developing oncolytic virus therapies and diagnostics for cancer and serious viral infections.
Japan 4588
Oncopeptides Logo
Develops targeted therapies for hematological cancers using peptide-drug conjugate technology.
Sweden ONCO
Onesano S.A. Logo
Develops patented nutritional products for humans, animals, and agriculture.
Poland SKT
ONO PHARMACEUTICAL CO., LTD. Logo
Develops innovative medicines for high unmet needs in oncology, immunology, and neurology.
Japan 4528
OPKO Health Inc. Logo
Provides clinical diagnostics & develops novel therapies for serious & pediatric diseases.
Israel OPK
OPTUS Pharmaceutical Co., Ltd. Logo
Develops and manufactures ophthalmic solutions for dry eye, infections, and inflammation.
South Korea 131030
Oramed Pharmaceuticals Inc. Logo
Develops oral drug delivery systems to turn injectable drugs, like insulin, into oral therapies.
Israel ORMP
Orexo Logo
Develops pharmaceuticals & digital health for opioid use disorder in the US market.
Sweden ORX

Talk to a Data Expert

Have a question? We'll get back to you promptly.